Crispr Therapeutics AG vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Crispr Therapeutics AG trades at $53.96 (market cap $5.23B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.91. The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PDBC | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | — |
52-Week High | $76.78 | $18.91 |
52-Week Low | $44.34 | $12.90 |
Enterprise Value | $3.65B | — |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →